{
    "title": "110_hr3368",
    "content": "The Act may be cited as the \"Pulmonary Hypertension Research and Education Act of 2007\". The Congress finds that pulmonary hypertension is a serious and often fatal condition where blood pressure in the lungs rises to dangerously high levels, leading to heart enlargement and failure. Federal investment in pulmonary hypertension research must be expanded to find a cure or effective treatment. The right side of the heart pumps harder to move blood into the lungs, causing enlargement and potential failure. Collaboration among pulmonary hypertension research centers needs to increase for effective treatment. Pulmonary hypertension is difficult to diagnose and often goes unnoticed in routine medical exams, with symptoms easily confused with other heart and lung conditions. Pulmonary hypertension is challenging to diagnose, often missed in routine exams, and symptoms can be mistaken for other heart and lung conditions. Collaboration among top research centers must increase for better treatment. In advanced stages, patients have limited activity and experience symptoms even at rest. New diagnostic standards have improved diagnosis rates. In advanced stages of pulmonary hypertension, patients have limited activity and symptoms even at rest, leading to considerable disability. The disease can progress to the point of complete bedriddenness. The National Heart, Lung, and Blood Institute established the first pulmonary hypertension patient registry in 1981, following 194 individuals with the condition. The National Heart, Lung, and Blood Institute established the first pulmonary hypertension patient registry in 1981, following 194 individuals with the condition for at least one year, providing valuable insights into the illness. The cause of pulmonary hypertension is still not fully understood, and there is currently no cure available. The registry followed 194 people with pulmonary hypertension for at least one year, providing valuable insights into the illness. Research is focusing on immunologic and genetic factors in the cause and progression of pulmonary hypertension. Research studies are investigating immunologic and genetic factors in the cause and progression of pulmonary hypertension, looking at agents that narrow pulmonary blood vessels and factors that promote cell growth and scar tissue formation in vessel walls. Currently, there are six FDA-approved medications for pulmonary hypertension with more in trials. Research is progressing in identifying factors causing endothelial and smooth muscle cell growth and scar tissue formation in vessel walls. There are six FDA-approved medications for pulmonary hypertension, with more in trials. However, not all medications are effective for all patients, and treatments have significant negative side effects. Lung transplantation is a last resort treatment for pulmonary hypertension. The number of physicians treating pulmonary hypertension and patients receiving treatment has significantly increased over the past decade, leading to a greater need for medical professional education. In 2001, there were 100 identified physicians treating pulmonary hypertension and 3,000 patients receiving treatment. The number of physicians treating pulmonary hypertension and patients receiving treatment has grown exponentially over the past decade. In 2001, there were 100 physicians treating pulmonary hypertension and 3,000 patients receiving treatment. By 2006, the number of physicians increased to 3,000 and patients to 30,000. Treatment now includes easy-to-administer oral therapies, but effective management remains complex. In 2006, there were 3,000 physicians and 30,000 patients receiving pulmonary hypertension treatment. While oral therapies are now available, effective management remains complex. Education of medical professionals is crucial for optimal patient care. Communication among researchers is crucial for future advancements in the fight against pulmonary hypertension. In December 2006, the National Heart, Lung, and Blood Institute hosted a meeting with over 500 attendees, emphasizing the importance of education for medical professionals in managing this disease. The Public Health Service Act is amended to include a section on pulmonary hypertension research and training. The Director of the Institute will expand research on pulmonary hypertension and establish a Pulmonary Hypertension Clinical Research Network to conduct clinical trials for new treatment approaches. The Director of the Institute will establish a Pulmonary Hypertension Clinical Research Network to conduct clinical trials for new treatment approaches. The network will consist of at least 15 clinical centers and an institute project scientist appointed by the Director. The Pulmonary Hypertension Clinical Research Network will include 15 clinical centers, an institute project scientist, a data and coordinating center, a data and safety monitoring board, and a steering committee. The Pulmonary Hypertension Clinical Research Network includes a steering committee comprised of principal investigators, a data and safety monitoring board, and an independent protocol review committee appointed by the Director. The Pulmonary Hypertension Clinical Research Network includes principal investigators, a data and coordinating center, an institute project scientist, an independent protocol review committee, and a steering committee responsible for determining specific clinical trials and establishing standards for subject selection. The steering committee appointed by the Director determines specific clinical trials for pulmonary hypertension, establishes subject selection standards, develops trial protocols, and analyzes and publishes results. Trials may include combination therapies and new drug therapy approaches based on cellular defects. Clinical trials for pulmonary hypertension include combination therapies, new drug therapy based on cellular defects, use of endothelial progenitor cells, and discovery of treatment effects predictive of long-term outcomes. The Institute is responsible for managing and supporting the network, including appointing an institute project scientist. The Institute is responsible for organizing and supporting the network, including appointing an institute project scientist to monitor subject recruitment and trial progress, ensure disclosure of conflicts of interest, and adherence to trial policies. The Institute shall monitor subject recruitment, trial progress, ensure disclosure of conflicts of interest, and manage fiscal aspects with the grants management specialist. The Institute manages subject recruitment, trial progress, conflict of interest disclosure, and fiscal aspects with the assistance of an institute grants management specialist appointed by the Director. The institute grants management specialist, appointed by the Director, assists the project scientist in fiscal management of the network. The Director also appoints members of various committees for the program. The Director appoints the Chair of the steering committee, members of the protocol review committee, and the data safety monitoring board. A grant program for pulmonary hypertension training will be implemented by the Director of the Institute within a year. The Director will establish a grant program for pulmonary hypertension training through a national nonprofit entity with expertise in the field. This program aims to educate and train medical professionals in various specialties. The national Pulmonary Hypertension Preceptorship and Training Program aims to educate and train medical professionals in clinical settings to effectively diagnose, treat, and manage pulmonary hypertension. The Pulmonary Hypertension Preceptorship and Training Program aims to train physicians in the United States to diagnose, treat, and manage pulmonary hypertension through regional training sites at academic health centers, hospitals, or private medical practices. The program aims to establish regional training sites across the United States at academic health centers, hospitals, or private medical practices for pulmonary hypertension training. Each site will have a designated contact, and a percentage of grant funds will be allocated for this purpose. The program establishes regional training sites for pulmonary hypertension training, each with a designated contact. Grant funds are allocated for this purpose, and mechanisms are established for participant recruitment. The nonprofit entity awarded the grant shall establish mechanisms for participant recruitment and program guidelines. Authorization of appropriations is provided for fiscal years 2009 through 2012. Increasing public awareness of pulmonary hypertension. The Secretary of Health and Human Services will develop and share information on pulmonary hypertension, including basic information, incidence, related diseases, importance of early diagnosis, and available treatments. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension through a national non-profit entity with expertise in the field. Authorization of appropriations will be provided for this purpose. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension through a national non-profit entity with expertise in the field, with authorized appropriations for fiscal years 2009 through 2012. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension through a national non-profit entity with expertise in the field. The Secretary of Health and Human Services will develop and disseminate information on pulmonary hypertension to healthcare providers, including warning signs, early diagnosis importance, diagnostic criteria, and FDA-approved therapies. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension to healthcare providers through a national non-profit entity with expertise in the disease. This includes details on warning signs, early diagnosis, diagnostic criteria, and FDA-approved therapies. Healthcare providers targeted include cardiologists, pulmonologists, rheumatologists, primary care physicians, pediatricians, and nurse practitioners. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension to healthcare providers through a national non-profit entity with expertise in the disease. Authorization of appropriations is provided for fiscal years 2009 through 2012. The Government Accountability Office will conduct a study on Medicare and Medicaid coverage standards. The Comptroller General of the United States will conduct a study on Medicare and Medicaid coverage standards for individuals with pulmonary hypertension, including all FDA-approved therapies. The study will consider appropriate delivery settings for these services and a report will be submitted to Congress within six months of the enactment of the Act. The Comptroller General will conduct a study on Medicare and Medicaid coverage standards for individuals with pulmonary hypertension, including all FDA-approved therapies, considering appropriate delivery settings. A report will be submitted to Congress within six months of the Act's enactment."
}